Sunday, July 11, 2021 1:20:14 PM
A simultaneous webcast will be available in the Investors section. A replay will be available for approximately three months following the conference.
Recent REPL News
- Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) • GlobeNewswire Inc. • 10/30/2024 01:15:09 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/16/2024 09:15:00 PM
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 10/09/2024 08:01:00 PM
- Replimune to Present at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 • GlobeNewswire Inc. • 09/15/2024 01:45:00 PM
- Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024 • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:05:15 PM
- Stockholders Vote to Elect Madhavan Balachandran to Board of Directors • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024 • GlobeNewswire Inc. • 08/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:00:04 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/15/2024 04:15:12 AM
- Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/08/2024 12:45:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 12:06:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:04:11 PM
- Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/08/2024 12:00:00 PM
- Replimune to Present at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 07/30/2024 08:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/19/2024 08:15:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/19/2024 08:15:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:36:13 PM
- Replimune Announces $100 Million Private Placement Financing • GlobeNewswire Inc. • 06/13/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:30:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 08:51:06 PM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM